Humanization of Murine Monoclonal anti-hTNF Antibody: The F10 Story

Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal...

Full description

Saved in:
Bibliographic Details
Published inMolecular biology (New York) Vol. 51; no. 6; pp. 921 - 926
Main Authors Efimov, G. A., Raats, J. M. H., Chirivi, R. G. S., van Rosmalen, J. W. G., Nedospasov, S. A.
Format Journal Article
LanguageEnglish
Published Moscow Pleiades Publishing 01.11.2017
Springer Nature B.V
Subjects
Autoimmune diseases
Biochemistry
Biomedical and Life Sciences
Comparative analysis
Current Trends in the Application of Monoclonal Antibodies Special Issue
Cytokines
Human Genetics
Inflammatory diseases
Infliximab
Life Sciences
Monoclonal antibodies
Pathogenesis
Tumor necrosis factor-TNF
Tumor necrosis factor-α
recombinant antibodies
tumor necrosis factor
TNF
humanized antibodies
Online AccessGet full text

Cover

More Information
Summary:Tumor necrosis factor (TNF) is a proinflammatory cytokine implicated in pathogenesis of multiple autoimmune and inflammatory diseases. Anti-TNF therapy has revolutionized the therapeutic paradigms of autoimmune diseases and became one of the most successful examples of the clinical use of monoclonal antibodies. Currently, anti-TNF therapy is used by millions of patients worldwide. At the moment, fully human anti-TNF antibody Adalimumab is the best-selling anti-cytokine drug in the world. Here, we present a story about a highly potent anti-TNF monoclonal antibody initially characterized more than 20 years ago and further developed into chimeric and humanized versions. We present comparative analysis of this antibody with Infliximab and Adalimumab.
ISSN:0026-8933
1608-3245
DOI:10.1134/S0026893317060061